Predict your next investment

Venture Capital
domainvc.com

See what CB Insights has to offer

Investments

571

Portfolio Exits

133

Funds

15

Partners & Customers

2

Service Providers

1

About Domain Associates

Founded in 1985, Domain was one of the first venture capital firms to exclusively invest in the life sciences sector. Domain has been involved in the formation of more than 260 companies. Today, with more than $2.7 billion in capital raised, Domain is a proven healthcare venture capital leader with solid investment returns from companies built to advance human health. Domain's primary investment areas are pharmaceuticals, diagnostics, and medical devices. The firm also evaluates and opportunistically invests in evolving sectors of the life sciences industry, such as healthcare IT, and technologies addressing specific healthcare issues, such as healthcare economics.

Domain Associates Headquarter Location

One Palmer Square Suite 515

Princeton, New Jersey, 08542,

United States

609-683-5656

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Domain Associates News

Exalys Launches With $15M to Treat Postoperative Delirium & More

Jul 20, 2020

Exalys Launches With $15M to Treat Postoperative Delirium & More Venture capitalists like nothing more than pattern matching, and Domain Associates has identified one it especially prefers: licensing drug candidates from a Japanese biopharma and setting up a US company to move it through testing until Big Pharma starts nosing around. It’s a roadmap the VC firm, which has offices in San Diego and Princeton, NJ, is looking to again follow with its latest investment: a $15 million Series A financing round that Domain and fledgling firm Catalys Pacific pulled together to launch Exalys Therapeutics. The new San Diego-based biotech plans to move ahead three potential drug candidates licensed from Japan’s Eisai that target EP4, a known cancer target that also plays a role in neuroinflammation. Domain and Catalys, which launched in 2019 with offices in Japan and in San Francisco, co-led the financing round for Exalys. Postoperative delirium is the first indication Exalys plans to go after. A complication that can follow surgery, the incidence of which increases as patients age, this form of delirium can prolong hospitalization, cause or accelerate cognitive decline, and result in a worsening quality of life. “We’re essentially taking what would be considered a preventive approach, not treating it once delirium manifests, but instead trying to prevent postoperative delirium from ever taking hold in a patient,” president and CEO Rick Orr told Xconomy. Exalys is evaluating which of the Eisai candidates to move ahead first, and plans to ask the FDA for permission to start human testing of the one it selects as its lead in the second half of 2021, he said. The potential treatment would be given daily by mouth for a day or two prior to surgery, then for up to week afterward. The idea is to tamp down the activity of EP4 during and after the procedure. “The surgical procedure is the trigger that would cause the neuroinflammatory response, so you’d want to have the drug on board, so to speak, and present during the time of surgery so it can have an impact as EP4 starts to have an effect, and you want to continue having that drug present,” Orr said. “Postoperative delirium in most patients is experienced for three to four days following surgery, so it’s not just a brief episode that lasts for a few hours and goes away, but typically lasts for several days.” In clinical trials the company plans to focus on patients age 65 and older who are slated for surgical procedures that are more likely to lead to an episode of postoperative delirium, he says. The condition is likelier to arise following major operations, such as cardiac or abdominal surgery, rather than less risky procedures. The company also plans to use biomarkers to identify patients most likely to benefit. Exalys is also considering other neuroinflammatory conditions the EP4 antagonists could potentially address. Orr has worked with Domain partners Eckard Weber and Dennis Podlesak for nearly 20 years. Their first foray was at Domain-backed Peninsula Pharmaceuticals, where Podlesak was CEO and Orr general counsel. Peninsula licensed assets from Japan’s Shionogi and developed them until Johnson & Johnson (NYSE: JNJ ) came calling. J&J acquired the firm for $245 million in 2005. Orr and Podlesak soon reunited in the same respective roles at Cerexa Pharmaceuticals, which moved ahead a drug candidate licensed from Takeda Pharmaceutical (NYSE: TAK ) until it was snapped up by Forest Laboratories in 2006 for $480 million. Weber was on the board. After the Cerexa acquisition Podlesak joined Domain, and when he and Weber launched antibiotics developer Calixa to develop a drug candidate from Astellas Pharma, Orr joined as chief operating officer. Calixa was bought in 2009 by Cubist Pharmaceutics, which later merged with Merck (NYSE: MRK ). “We’ve got a long history of working together, building companies, successfully advancing compounds and ultimately transacting those companies,” Orr said. “In all of those companies what’s important to me, and I think to Dennis and Eckard as well, is that they went on to successful product approvals, so it’s good to see that you’ve selected sound science that is sufficiently interesting to large pharma that they pick it up and continue to advance the compounds.” Most recently Orr was head of pain drug developer Adynxx (NASDAQ: ADYX ), another Domain-backed company, which last year went public via reverse merger with Alliqua BioMedical. Adynxx founder and chief scientific officer Julien Mamet and Bill Martin, who handled corporate development, marketing, and commercial strategy, also made the move to Exalys, Mamet as CSO and Martin as executive vice president, corporate development and operations. The four-person operation will roughly double its headcount over the next 12 to 18 months, Orr said. Image: iStock/Motortion Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com. Follow @sarahdc

Domain Associates Investments

571 Investments

Domain Associates has made 571 investments. Their latest investment was in ChromaCode as part of their Unattributed VC on March 3, 2022.

CBI Logo

Domain Associates Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/3/2022

Unattributed VC

ChromaCode

$27.97M

No

1

11/3/2021

Series B - II

Antios Therapeutics

$75M

No

11

10/13/2021

Series A - II

Seraphina Therapeutics

$5M

No

3

5/27/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

4/12/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/3/2022

11/3/2021

10/13/2021

5/27/2021

4/12/2021

Round

Unattributed VC

Series B - II

Series A - II

Series C

Series B

Company

ChromaCode

Antios Therapeutics

Seraphina Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$27.97M

$75M

$5M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

11

3

10

10

Domain Associates Portfolio Exits

133 Portfolio Exits

Domain Associates has 133 portfolio exits. Their latest portfolio exit was OmniOme on July 20, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/20/2021

Acquired

$99M

7

7/16/2021

IPO

$99M

1

4/22/2021

IPO

$99M

10

12/16/2020

Acquired

Subscribe to see more

Subscribe to see more

10

10/16/2019

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/20/2021

7/16/2021

4/22/2021

12/16/2020

10/16/2019

Exit

Acquired

IPO

IPO

Acquired

Acq - P2P

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

7

1

10

10

10

Domain Associates Acquisitions

1 Acquisition

Domain Associates acquired 1 company. Their latest acquisition was Cardiodynamics International Corporation on June 21, 1999.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/21/1999

Other Venture Capital

$99M

$23.5M

Acquired

Date

6/21/1999

Investment Stage

Other Venture Capital

Companies

Valuation

$99M

Total Funding

$23.5M

Note

Acquired

Sources

Domain Associates Fund History

15 Fund Histories

Domain Associates has 15 funds, including Domain Partners IX.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/7/2016

Domain Partners IX

Early-Stage Venture Capital

Open

$163.63M

3

9/30/2009

DP VIII Associates LP

Multi-Stage Venture Capital

Closed

$4M

1

6/18/2009

Domain Partners VIII

Multi-Stage Venture Capital

Closed

$371.07M

1

12/31/2006

DP VII Associates LP

Subscribe to see more

Subscribe to see more

$99M

10

8/24/2006

Domain Partners VII

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/7/2016

9/30/2009

6/18/2009

12/31/2006

8/24/2006

Fund

Domain Partners IX

DP VIII Associates LP

Domain Partners VIII

DP VII Associates LP

Domain Partners VII

Fund Type

Early-Stage Venture Capital

Multi-Stage Venture Capital

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Open

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$163.63M

$4M

$371.07M

$99M

$99M

Sources

3

1

1

10

10

Domain Associates Partners & Customers

2 Partners and customers

Domain Associates has 2 strategic partners and customers. Domain Associates recently partnered with Rusnano on August 8, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

8/11/2016

Partner

Russian Federation

Media About Us, Media Center, RMI Partners

Through this partnership , Pfizer Inc. proposes to invest in NovaMedica 's construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner .

1

3/13/2013

Partner

China

Subscribe to see more

Subscribe to see more

10

Date

8/11/2016

3/13/2013

Type

Partner

Partner

Business Partner

Country

Russian Federation

China

News Snippet

Media About Us, Media Center, RMI Partners

Through this partnership , Pfizer Inc. proposes to invest in NovaMedica 's construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner .

Subscribe to see more

Subscribe to see more

Sources

1

10

Domain Associates Service Providers

1 Service Provider

Domain Associates has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Domain Associates Team

3 Team Members

Domain Associates has 3 team members, including current Controller, Lisa Kraeutler.

Name

Work History

Title

Status

Lisa Kraeutler

Controller

Current

Jesse I. Treu

Founding Partner

Current

Debra K. Liebert

Managing Director

Current

Name

Lisa Kraeutler

Jesse I. Treu

Debra K. Liebert

Work History

Title

Controller

Founding Partner

Managing Director

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.